A new type of gene therapy that only activates when the brain is under stress could stop epilepsy before it fully develops, researchers say. 

In a study led by Professor Tawfeeq Shekh-Ahmed of the School of Pharmacy at the Hebrew University of Jerusalem (HU), published in Signal Transduction and Targeted Therapy, scientists engineered a therapy which is designed to respond only when needed. 

The therapy uses a built-in biological ‘sensor’ that detects when brain cells become overactive, as they do during seizures, and then turns on a protective response. 

A protein known as Nrf2 is central to the process, known for its ability to protect cells from oxidative stress, a damaging process linked to seizures and brain injury. Activating Nrf2 all the time can interfere with normal brain function, so researchers paired it with a genetic switch called cfos, which is naturally activated only in highly active neurons. 

 The result is a therapy that turns on antioxidant protection only in overactive brain cells, and only at the right time, during a seizure. 

 In preclinical research, the treatment reduced seizure severity, lowered overall seizure burden, and increased the number of seizure-free periods. It also showed benefits in memory, behaviour, and overall brain function-areas often affected in people living with epilepsy. 

 The therapy also remained effective even when introduced after the disease process had begun, suggesting it could be administered to patients with long-standing or drug-resistant epilepsy. 

“Our goal was to create a treatment that works with the brain, not against it,” Shekh-Ahmed said.  

“Instead of constant intervention, we wanted something that activates only during harmful activity. 

“This is a proof of concept for a smarter kind of therapy. One that is precise, adaptive, and minimises unwanted side effects.”